Newsroom

For media enquiries or more information about Communications at the 
Djavad Mowafaghian Centre for Brain Health, please contact:

Emily Wight, Communications Manager
Email: emily.wight@brain.ubc.ca | Phone: 604.827.3396

Changing the pace of memory loss Dec 9, 2014

Researchers at the Djavad Mowafaghian Centre for Brain Health, in collaboration with scientists at the Chongqing Medical University in Chongqing, China, recently discovered a way to slow the deterioration of memory. These findings significantly advance our understanding of the mechanism by which memory in our brain decays, and are the first to establish an opportunity for intervention to slow the progression of Alzheimer’s disease (AD) and related dementias.

+
NMO Clinic and Research Program joins multi-centre study Nov 20, 2014

Collaborative International Research in Clinical and Longitudinal Experience for NMO Studies

In North America, Neuromyelitis Optica (NMO) affects four in 100,000 people, and can cause loss of vision in one or both eyes (optic neuritis) and numbness and weakness in the arms and legs (transverse myelitis). It is an unpredictable and chronic illness that is often confused with Multiple Sclerosis, but NMO is a distinct disease requiring different treatment. 

+
Teen girls playing soccer
Teenage brains may be more vulnerable to lasting injury Nov 19, 2014

Young athletes who experience concussions may need to wait longer than currently recommended before getting ‘back in the game’ because of the unique brain developmental stage of adolescence, according to new research. The study, published in the Journal of Neurotrauma, shows that current adult-based standards for assessing the effects of concussions and length of time to recovery may be inadequate for adolescents.

+
Predicting adverse drug reactions in patients with Multiple Sclerosis Nov 17, 2014

Interferon beta (IFN-β) is a disease-modifying drug used to reduce the risk of a future relapse (attacks) in people with multiple sclerosis (MS) by modulating the immune system. And while IFN-β is considered safe, it does hold a small possibility of side effects, including liver injury. While 30 to 60 per cent of individuals with MS treated with IFN-β will experience elevations in their liver enzyme test results, these elevations are often transient and disappear even with continued IFN-β treatment. 

+
Neuromyelitis Optica (NMO) Information Day Oct 23, 2014

The third annual Neuromyelitis Optica (NMO) Information Day will be held at the Djavad Mowafaghian Centre for Brain Health (DMCBH) on November 1, from 10:00 a.m. to 4:00 p.m.

+
Researcher profile: Dr. Haakon Nygaard Oct 21, 2014

Dr. Haakon Nygaard comes to the Djavad Mowafaghian Centre for Brain Health (DMCBH) from Yale University, where he completed his internship in Internal Medicine, Residency in Neurology, and a PhD in Investigative Medicine under the mentorship of Dr. Stephen Strittmatter. He joined the Yale faculty as an Assistant Professor in Neurology, and during this time he co-founded the first Alzheimer’s clinic at Yale, and was the founding director of the Yale Behavioral Neurology and Neuropsychiatry fellowship program. Dr.

+
Researcher profile: Dr. Dan Marigold Oct 16, 2014

In order to pursue discovery and improve the mobility of people with eye disease and other neurological conditions, Dr. Marigold’s research combines basic science with clinically relevant scenarios.

+
Researcher profile: Dr. Carles Vilarino-Guell Oct 15, 2014

Molecular geneticist Dr. Carles Vilarino-Guell has played an important role in the identification of the genes that carry mutations responsible for the onset of neurological diseases such as Parkinson’s and Multiple Sclerosis.

+
Novel communication between neurons and the brain’s immune cells Oct 14, 2014

Pictured:The dendrites of one neuron (red), and microglial cells (green).

Researchers in Dr. Brian MacVicar’s lab recently established a novel communication pathway between neurons and microglia, the brain’s immune cells.

+
Canadian diamond pioneer donates $9.1 million for Alzheimer’s research Sep 30, 2014

The quest to understand and treat Alzheimer’s disease is being bolstered intellectually and technologically thanks to three gifts to from Charles Fipke, whose geological discoveries made Canada one of the leading producers of diamonds.

Fipke has given $3 million to endow a professorship dedicated to Alzheimer’s research, and has pledged $600,000 to outfit the professor’s lab with cutting-edge equipment at the Djavad Mowafaghian Centre for Brain Health. He has also committed $5.5 million to support the purchase of the most novel and coveted brain imaging technology.

+

Pages